Navigation Links
Covington Advises AstraZeneca in $1.26 Billion Acquisition of Ardea Biosciences
Date:4/23/2012

WASHINGTON, April 23, 2012 /PRNewswire/ --  Covington & Burling represented AstraZeneca in its $1.26 billion acquisition of Ardea Biosciences.  Under the agreement, AstraZeneca will pay $32 per share for all of the outstanding shares of Ardea. 

(Logo: http://photos.prnewswire.com/prnh/20120423/CL92331LOGO )

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. Ardea is a biotechnology company based in San Diego, California, focused on the development of small-molecule therapeutics for the treatment of serious diseases. 

The Covington team was led by Catherine Dargan, with assistance from Stephen Infante and Michael Riella. The team also included John Hurvitz, Emily Leonard, Ashley Nelson, Darien Capron, Brianna Sandoval, Christina Chung, Larry Bartenev and Caitlin Cottingham (life sciences/corporate), Robert Heller and Sarah Burnham (tax), Michael Francese and Katherine Mineka (benefits), Marialuisa Gallozzi and Scott Levitt (insurance), Andrea Reister and Marie Lavalleye (intellectual property), Michael Labson (regulatory), and Deborah Garza, James Dean and Jonathan Herczeg (antitrust). 

Covington & Burling LLP, an international law firm, provides corporate, litigation, and regulatory expertise to enable clients to achieve their goals.  Founded in 1919, the firm has more than 800 lawyers and offices in Beijing, Brussels, London, New York, San Diego, San Francisco, Silicon Valley, and Washington, DC.

Contact

Rebecca Carr


202.662.5110


rcarr@cov.com


'/>"/>
SOURCE Covington & Burling
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. nanoTox COO Greg King Advises Nanotech Companies to View Safety Concerns as an Opportunity to Gain Consumer Trust
2. KTA Capital Advises SpringTree Global Investors on an AU$25.5 Million Investment in Prima BioMed Ltd
3. Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
4. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
5. Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
6. AstraZeneca and Sarah Cannon Research Institute Join Efforts to Fight Cancer
7. Combined Sales of Seven Emerging Therapies for Breast Cancer, Including Drugs From Sanofi-Aventis and AstraZeneca, Will Total Nearly $5 Billion by 2019
8. Rigel Earns Milestone Payments From AstraZeneca
9. TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis
10. AstraZeneca Outlines Principles for Product-Related Online Communications
11. AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... ... and Electrospraying line of nanofiber and nanoparticle fabrication instruments ... the lab to fully automated pilot plants and equipment for industrial manufacturing. ...
(Date:8/16/2017)... edition of the Inc. 5000 features a now-familiar name: BioPoint ( http://biopointinc.com/ ... list for the third year in a row. Now in its 36th ... a set of quantitative metrics. In addition, BioPoint was also named to ... Bay State . ... ...
(Date:8/15/2017)... ... 2017 , ... Pittcon is pleased to once again co-program ... This year’s symposium, organized by the Pittcon 2018 program chair, Annette Wilson, (University ... dynamic presentation will discuss novel ionization processes, high throughput IMS-MS technologies, and top ...
(Date:8/15/2017)... ... August 15, 2017 , ... JULABO USA introduces its ... new website makes it easy to navigate through the site whether you’re in ... detailed product information, educational industry content and visit the company’s social media accounts, ...
Breaking Biology Technology:
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
Breaking Biology News(10 mins):